|
Washington University Molecular Imaging Center
|
2P50CA094056-12
|
$1,428,925
|
$85,736
|
PIWNICA-WORMS, DAVID
|
WASHINGTON UNIVERSITY
|
|
Vasculogenesis in Ewing's Sarcoma: Implications for Therapy
|
5R01CA103986-08
|
$246,403
|
$61,601
|
Kleinerman, Eugenie
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors
|
1P01CA154291-01A1
|
$1,651,535
|
$346,822
|
BIGNER, DARELL
|
DUKE UNIVERSITY
|
|
Use of nanogels to target delivery of siRNA to cancer cells in mice
|
5R21CA155479-02
|
$247,687
|
$247,687
|
McDonald, John
|
GEORGIA INSTITUTE OF TECHNOLOGY
|
|
University of Texas SPORE in Lung Cancer
|
5P50CA070907-15
|
$2,300,000
|
$460,000
|
MINNA, JOHN
|
UNIV OF TX SW MED CTR-DALLAS
|
|
University of Texas M.D. Anderson Cancer Center SPORE - Leukemia
|
5P50CA100632-10
|
$2,300,000
|
$184,000
|
Kantarjian, Hagop
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Understanding and Eliminating Oncogenic EGFR Signaling in Malignant Glioma
|
5U01CA141556-04
|
$660,126
|
$165,032
|
Charest, Alain
|
TUFTS MEDICAL CENTER
|
|
UCLA Tumor Immunology Training Program
|
2T32CA009120-36A1
|
$432,554
|
$86,511
|
TEITELL, MICHAEL
|
UNIVERSITY OF CALIFORNIA AT LOS ANGELES
|
|
UCLA Tumor Immunology Training Program
|
3T32CA009120-36A1S1
|
$30,666
|
$6,133
|
TEITELL, MICHAEL
|
UNIVERSITY OF CALIFORNIA AT LOS ANGELES
|
|
U1 Adaptor:Dendrimer silencing of BCL2 for tumor suppression.
|
3R43CA153842-01S1
|
$62,100
|
$62,100
|
Goraczniak, Rafal
|
SILAGENE, INC.
|
|
Transport of Large Molecules and Viral Vectors in Tumors: Effects of Cytotoxic an
|
5R01CA098706-09
|
$278,762
|
$278,762
|
BOUCHER, YVES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Translational Breast Cancer Research Training Program
|
5T32CA090221-10
|
$183,921
|
$45,980
|
FUQUA, SUZANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Transgenic in vivo delivery of MDA7/IL24 for maligannt glioma therapy
|
5R01CA129489-05
|
$341,162
|
$341,162
|
GERMANO, ISABELLE
|
MOUNT SINAI SCHOOL OF MEDICINE
|
|
Transduction of T cells to improve migration to tumor
|
5R01CA116206-08
|
$335,525
|
$335,525
|
HWU, PATRICK
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Training Program in Molecular Oncology and Immunology
|
5T32CA009161-37
|
$752,950
|
$75,295
|
Levy, David
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
TRAINING IN CANCER BIOLOGY AND TRANSPLANTATION
|
5T32CA009515-28
|
$613,461
|
$613,461
|
APPELBAUM, FREDERICK
|
UNIVERSITY OF WASHINGTON
|
|
TRAINING GRANT IN VIRAL AND CHEMICAL CARCINOGENESIS
|
5T32CA009320-28
|
$269,591
|
$202,193
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Training Grant in Cancer Biology
|
5T32CA009126-35
|
$365,773
|
$120,705
|
MAY, William
|
UNIVERSITY OF FLORIDA
|
|
TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC
|
5R01CA109446-10
|
$258,455
|
$258,455
|
Griffith, Thomas
|
UNIVERSITY OF MINNESOTA
|
|
Therapeutic Potential of IL-15 Plasmid Delivery to Tumors Using Electroporation
|
5R01CA122518-05
|
$261,203
|
$261,203
|
HELLER, RICHARD
|
OLD DOMINION UNIVERSITY
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
5P50CA083639-13
|
$2,227,276
|
$267,273
|
BAST, ROBERT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Melanoma
|
5P50CA093459-08
|
$2,272,914
|
$136,375
|
GRIMM, ELIZABETH
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
The UCLA Center for In Vivo Imaging in Cancer Biology
|
5P50CA086306-13
|
$1,415,212
|
$169,825
|
Herschman, Harvey
|
UNIVERSITY OF CALIFORNIA AT LOS ANGELES
|
|
The Roles of HBXAP Gene in Ovarian Cancer
|
5R01CA129080-05
|
$330,091
|
$82,523
|
SHIH, IE-MING
|
JOHNS HOPKINS UNIVERSITY
|
|
The Role of Fbxw7 in genetic instability and cancer
|
5R01CA116481-06
|
$345,303
|
$120,856
|
Mao, Jian-Hua
|
UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB
|
|
The Regulation of Tumor Progression by Endothelial HoxA5
|
5R01CA140655-03
|
$310,970
|
$102,620
|
BOUDREAU, NANCY
|
UNIVERSITY OF CALIFORNIA-SAN FRANCISCO
|
|
The in vivo role of the mitochondrial p53 cell death program
|
5R01CA060664-17
|
$266,225
|
$133,113
|
MOLL, UTE
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
The GNAQ pathway as a therapeutic target in uveal melanoma
|
7R01CA142873-03
|
$310,970
|
$102,620
|
BASTIAN, BORIS
|
UNIVERSITY OF CALIFORNIA-SAN FRANCISCO
|
|
The adoptive transfer of gene-modified T cells as a cell therapy for lymphoma
|
5K08CA148821-03
|
$168,661
|
$168,661
|
Davila, Marco
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Texas Center for Cancer Nanomedicine
|
5U54CA151668-03
|
$2,538,514
|
$1,066,176
|
Gorenstein, David
|
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
|
|
TCR Gene Modified T Cells for Adoptive Immunotherapy
|
5P01CA154778-02
|
$3,493,020
|
$1,921,161
|
NISHIMURA, MICHAEL
|
LOYOLA UNIVERSITY CHICAGO
|
|
Targeting Translation Control in Malignant Glioma
|
2R01CA124756-06A1
|
$249,873
|
$249,873
|
GROMEIER, MATTHIAS
|
DUKE UNIVERSITY
|
|
Targeting the let-7-HMGA2 Network in Metastatic Progression in Pancreatic Cancer
|
1R03CA164677-01A1
|
$81,000
|
$40,500
|
RESAR, LINDA
|
JOHNS HOPKINS UNIVERSITY
|
|
Targeting Leukemic Stem Cells
|
5R01CA138211-05
|
$418,058
|
$418,058
|
TENEN, DANIEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
TARGETING EPIGENOMIC SIGNATURES IN NON-HODGKIN LYMPHOMA FOR NOVEL THERAPEUTICS
|
5R01CA156690-03
|
$314,488
|
$314,488
|
Oltz, Eugene
|
WASHINGTON UNIVERSITY
|
|
Targeted-and Image-Based Adenovirus Cancer Therapeutic Vectors
|
5R01CA154697-02
|
$472,780
|
$472,780
|
Curiel, David
|
WASHINGTON UNIVERSITY
|
|
Targeted therapy of ALL with gene-modified central memory T cells
|
5R01CA136551-04
|
$542,633
|
$271,317
|
Riddell, Stanley
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Targeted theranostic microbubble vectors for transcription factor decoy delivery
|
1R21CA167373-01
|
$165,844
|
$165,844
|
VILLANUEVA, FLORDELIZA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Targeted Nanoparticle DNA Therapy for Ovarian Cancer
|
5R01CA132091-05
|
$266,946
|
$266,946
|
SAWICKI, JANET
|
LANKENAU INSTITUTE FOR MEDICAL RESEARCH
|
|
Targeted Lipopolyplexes for Oligonucleotide Delivery to AML
|
5R01CA135243-05
|
$441,357
|
$441,357
|
Lee, Robert
|
OHIO STATE UNIVERSITY
|
|
Targeted Improvement in Stem Cell Therapy for Leukemia and Bone Marrow Failure Sy
|
5R01CA157537-02
|
$317,475
|
$317,475
|
PANG, QISHEN
|
CHILDREN'S HOSPITAL MEDICAL CENTER CINCI
|
|
Targeted Chemoprevention for Melanoma
|
5R01CA136667-03
|
$407,854
|
$407,854
|
ROBERTSON, GAVIN
|
PENNSYLVANIA STATE UNIVERSITY
|
|
Tailored antigen specificity for personalized adoptive T cell therapy of cancer
|
5R21CA152540-02
|
$208,800
|
$104,400
|
Powell, Daniel
|
UNIVERSITY OF PENNSYLVANIA
|
|
T-cell Therapy for B-lineage Acute Lymphoblastic Leukemia
|
5R01CA141303-03
|
$318,015
|
$318,015
|
COOPER, LAURENCE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Synergistic chemo-siRNA combination therapy
|
5R01CA158300-02
|
$372,483
|
$372,483
|
WIENTJES, M
|
OPTIMUM THERAPEUTICS, LLC
|
|
Surgical Oncology Research Training Program
|
5T32CA132715-05
|
$134,097
|
$134,097
|
VICKERS, SELWYN
|
UNIVERSITY OF MINNESOTA
|
|
Surface-modified pharmaceutical nanocarriers for subcellular targeting
|
5R01CA128486-05
|
$300,503
|
$150,252
|
TORCHILIN, VLADIMIR
|
NORTHEASTERN UNIVERSITY
|
|
Studies of the role of microRNA miR-16-1 in the NZB mouse model of CLL
|
5R01CA129826-03
|
$313,989
|
$78,497
|
RAVECHE, ELIZABETH
|
UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL
|
|
Strategies to Enhance Virotherapy for Breast Cancer
|
5R01CA106671-09
|
$218,246
|
$109,123
|
ZHANG, XIAOLIU
|
UNIVERSITY OF HOUSTON
|
|
Sten Cell Gene Therapy of Breast Cancer
|
5R01CA136487-04
|
$313,989
|
$313,989
|
LIEBER, ANDRE
|
UNIVERSITY OF WASHINGTON
|
Total relevant funding to Gene Therapy for this search: $58,732,525
|